The study, sponsored by Universitaire Ziekenhuizen KU Leuven, aims to develop a non-invasive diagnostic tool for asthma by utilizing mRNA analysis of sputum. This approach could significantly enhance the precision of asthma treatment by identifying distinct molecular phenotypes, which may lead to tailored therapeutic strategies. The market for asthma treatments is substantial, with increasing demand for personalized medicine solutions. The findings could position the sponsor as a leader in asthma diagnostics, potentially attracting partnerships or licensing opportunities. However, the competitive landscape includes established players in asthma management, necessitating a robust commercialization strategy.